AZN•benzinga•
AstraZeneca's High-Level Results From POTOMAC Phase 3 Trial Showed One Year Of Treatment With Imfinzi (Durvalumab) Plus Standard-of-care Bacillus Calmette-guérin (BCG) Induction And Maintenance Therapy Demonstrated Improvement In Disease-Free Survival For
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 9, 2025 by benzinga